Valo Therapeutics is an immunotherapy company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.
Valo Therapeutics has raised $20.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2025.
Valo Therapeutics's investors include CDP Venture Capital, European Innovation Council, Business Finland, Indaco Venture Partners, ENEA Tech e Biomedical.
Valo Therapeutics is headquartered in Helsinki, Finland.
Valo Therapeutics is an immunotherapy company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.
Valo Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Valo Therapeutics — Funding & Investors." VCBacked, March 10, 2025, https://www.vcbacked.co/company/valo-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Valo Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/valo-therapeutics
{{cite web |title=Valo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/valo-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated